جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

54 مُخرَج نتائج البحث عن «Insulin»

مقالوصول مفتوح20261استشهاد· Semantic Scholar

L-Serine Attenuates Metabolic and Behavioural Features of Diabetic Neuropathy with Dose-Dependent Central Proteomic Correlates in a Rat Model

Biomolecules · مجلد 16 (6) · 881-881

Diabetic neuropathy (DN) is a multifactorial complication of diabetes mellitus driven by chronic hyperglycemia, insulin resistance, and disturbed metabolic homeostasis, leading to progressive injury of both the peripheral and central nervous systems. This study investigated whether L-serine supplementation could attenuate DN through dose-dependent metabolic and neuroprotective mechanisms in a high-fat diet (HFD) plus streptozotocin (STZ)-induced diabetic rat model. Male Wistar rats (n = 8 per group) were allocated to five groups: normal control (NC), diabetic control (DC), pioglitazone (PIO; 1.5 mg/kg/day), low-dose L-serine (S1; 200 mg/kg/day), and high-dose L-serine (S2; 400 mg/kg/day). After 60 days of oral gavage, behavioural testing, glucose and insulin profiling, HOMA-IR calculation, brain histopathology, nerve growth factor (NGF) immunohistochemistry, and LC–MS/MS-based proteomic analysis of cerebral tissue were performed. Diabetic rats exhibited marked hyperglycaemia (355.33 ± 4.72 mg/dL), hyperinsulinaemia, severe insulin resistance (HOMA-IR 16.8 ± 3.2; a 14-fold increase), impaired thermal nociception, motor dysfunction, and pronounced neuronal degeneration. L-serine supplementation significantly improved metabolic status: S1 reduced HOMA-IR by 77.4% and S2 by 87.5% relative to diabetic controls (p < 0.001). High-dose L-serine produced greater improvements in thermal sensitivity, motor coordination (rotarod latency 26.67 ± 1.52 s vs. 16.1 ± 0.85 s in DC; p < 0.05), and NGF expression (8.6-fold increase vs. DC). Histopathology confirmed attenuation of neuronal injury and gliosis in both treatment groups. Exploratory, group-level proteomic profiling identified dose-specific molecular signatures: S1 was predominantly associated with carbohydrate, lipid, and biosynthetic pathways, whereas S2 was associated with synaptic, neurotransmission-related, and proteostasis pathways. Within the constraints of an exploratory design—group-level pooled proteomics, analysis of cerebral rather than peripheral-nerve tissue, and only two doses—these findings indicate that L-serine attenuates the metabolic and behavioural features of experimental diabetic neuropathy and generates the testable hypothesis of dose-dependent neuro-metabolic remodelling. The proteomic signatures are hypothesis-generating and require orthogonal validation before any mechanistic or translational inference can be drawn.

diabetic neuropathyinsulin resistancehyperglycemiastreptozotocin-induced diabetes
مقالوصول مفتوح2026

Medication Adherence Among Adults with Diabetes in Jazan, Saudi Arabia: Role of Pharmacist Support and Digital Health

Patient Preference and Adherence · مجلد Volume 20 · 1-21

Background: Medication adherence is critical for achieving optimal glycemic control and preventing diabetes-related complications. However, poor adherence remains a major barrier to effective diabetes management worldwide. Evidence regarding factors associated with medication adherence among adults with diabetes in Saudi Arabia remains limited. This study aimed to assess medication adherence among adults with diabetes and examine associations of sociodemographic, clinical, pharmacist-related, and digital health factors with adherence levels. Methods: A cross-sectional study was conducted among adults with type 1 or type 2 diabetes attending a specialized diabetes center in Jazan, Saudi Arabia, during February-March 2025. Participants were recruited using non-probability convenience sampling. Of 489 patients approached, 388 completed the questionnaire, yielding a response rate of 79.3%. Data were collected using a bilingual (Arabic/English) electronic questionnaire. Medication adherence was assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8). Descriptive statistics, bivariate analyses, correlation analysis, and multinomial logistic regression were performed using IBM SPSS Statistics version 27. Results: Overall, 77.1% of participants demonstrated low medication adherence, while 16.5% and 6.4% demonstrated moderate and high adherence, respectively. In the adjusted multinomial logistic regression model, higher satisfaction with the current diabetes management plan was significantly associated with greater odds of moderate adherence (OR=1.650, 95% CI: 1.212-2.245, P=0.001) and high adherence (OR=2.038, 95% CI: 1.165-3.565, P=0.013) compared with low adherence. Insulin use was associated with moderate vs low adherence (OR=2.175, 95% CI: 1.008-4.692, P=0.048), but not with high adherence. Participants who did not use mobile applications or digital health tools had higher odds of high vs low adherence than those who used such tools (OR=2.685, 95% CI: 1.007-7.154, P=0.048). Age and comorbid conditions were not significantly associated with adherence level in the adjusted model. Frequency of pharmacist consultation was significant overall (P=0.001), although individual category comparisons did not demonstrate a consistent pattern across adherence levels. Multicollinearity diagnostics indicated no problematic collinearity (VIF=1.04-1.34; tolerance ≥0.75). Conclusion: Medication adherence was predominantly low among study participants. Higher satisfaction with diabetes management was consistently associated with greater adherence, while insulin use and digital health tool use showed category-specific associations. The unexpected association between digital-tool non-use and high adherence should be interpreted cautiously and does not establish a causal effect of digital technology on adherence. Further longitudinal and prospective studies are warranted to clarify these associations and determine how structured pharmacist engagement and personalized digital-health strategies can be optimally incorporated into patient-centered diabetes care.

medication adherencediabetes mellitustype 1 diabetestype 2 diabetes
مقالوصول مفتوح2026

Occupational Organophosphorus Pesticide Exposure and Metabolic Syndrome: Implications of PPARγ

Toxics · مجلد 14 (9) · 788-788

Organophosphorus pesticides (OPPs) are widely used and have recently been linked to metabolic syndrome (MS). This study aimed to investigate the probable association between chronic OPP exposure and MS among farm workers in Sharkia Governorate, Egypt, and to assess the potential role of peroxisome proliferator-activated receptor gamma (PPARγ). This comparative cross-sectional study included 140 participants, equally divided into OPP-exposed farm workers and non-exposed subjects. OPP exposure was confirmed by detecting plasma residues and cholinesterase activity. MS was diagnosed by assessing body mass index (BMI), waist circumference (WC), blood pressure, plasma glucose, serum insulin, and lipid parameters. Oxidative and inflammatory markers, including malondialdehyde (MDA), gamma-glutamyl transferase (GGT), ferritin, superoxide dismutase (SOD), tumor necrosis factor-alpha (TNF-α), and high-sensitivity C-reactive protein (hs-CRP), were measured. The mRNA expression of the PPARγ and paraoxonase 1 (PON1) genes was also investigated. In total, 60% of farm workers demonstrated MS, compared with 10% of non-exposed participants. Workers exhibited elevated oxidative and inflammatory indices and reduced PPARγ and PON1 expression. PPARγ positively correlated with high-density lipoprotein (HDL), SOD, and PON1, while negatively correlating with glucose, insulin resistance (IR), low-density lipoprotein (LDL), triglycerides (TGs), MDA, GGT, ferritin, TNF-α, and hs-CRP. The study concluded that chronic OPP exposure was associated with increased oxidative stress and inflammation, reduced PPARγ and PON1 expression, disturbed glucose and lipid metabolism, and increased IR. The observed associations between PPARγ downregulation, metabolic disturbances, and oxidative and inflammatory markers suggest that PPARγ dysregulation may represent a potential mechanistic link between chronic OPP exposure and MS. However, this proposed mechanism requires further validation.

organophosphorus pesticidesoccupational pesticide exposurefarm workersmetabolic syndrome
مراجعةوصول مفتوح2026

Hepatoprotective effects of empagliflozin in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of preclinical studies

Frontiers in Pharmacology · مجلد 17 · 1822157-1822157

Background: The worldwide burden of metabolic dysfunction-associated steatotic liver disease (MASLD) is rising sharply, powered by high prevalence of obesity and its associated metabolic insults. Though urgent, definitive treatment is not yet available. Empagliflozin, a sodium glucose co-transporter inhibitor has been suggested in both human and animal studies to have diverse beneficial effects in MASLD by anti-inflammation and anti-oxidative stress effects, but many of the underlying mechanisms remain unexplained. The main aim of this systematic review and meta-analysis was to evaluate the effects of empagliflozin's in preclinical animal studies trying to view new horizons for future treatment of MASLD. Methods: we searched the related animal preclinical studies in databases including Scopus, Web of Science, Cochrane library, Wily online library and PubMed. The research team screened the literature and extracted data; any discrepancies were resolved by the research team leader through discussion. The quality of research methods was assessed by SYRCLE (systematic review center for laboratory animal experimentation) risk of bias tool. The meta-analysis was guided by the Cochrane Handbook; statistical analyses were conducted via RevMan 5.4 offline version and Comprehensive Met analysis V3 software. Results: Our meta-analysis included 17 studies, involving 584 animals. In comparison with the model group, empagliflozin significantly reduced steatosis markers including hepatic burden of lipids, including triglycerides and cholesterol, NAFLD Activity Score (NAS) and total serum cholesterol (TC). It also significantly reduced hepatic fibrosis markers including fibrosis grade, transforming growth factor-β (TGF-β) and collagen type I alpha 1 chain) COL1A1). Beyond its anti-steatofibrotic effects, empagliflozin significantly downregulated hepatic expression of inflammatory and oxidative markers including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and malondialdehyde (MDA). Moreover, empagliflozin significantly improved glycemic indices including Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), serum insulin, and fasting blood sugar (FBS). Conclusion: Empagliflozin significantly protected the liver against steatosis and fibrosis by mitigating hepatic inflammation, oxidative stress and insulin resistance.

empagliflozinnon-alcoholic fatty liver diseaseSGLT2 inhibitorshepatic steatosis
مراجعةوصول مفتوح2026

Bone Mineral Density Changes and Metabolic Risk Factors in Patients with Rheumatoid Arthritis on Long-Term Therapy: A Narrative Review

International Journal of Clinical and Medical Research · مجلد 3 (1) · 22-26

Rheumatoid Arthritis (RA) is a chronic systemic inflammatory disease associated with progressive joint damage and important extra-articular complications, including osteoporosis, reduced Bone Mineral Density (BMD), fragility fractures, metabolic syndrome, insulin resistance, dyslipidemia, sarcopenia and cardiovascular disease. Chronic inflammation, reduced physical activity, altered body composition, nutritional deficiencies and long-term pharmacological therapy contribute to these complications. Glucocorticoids are particularly important because prolonged exposure may reduce bone formation and adversely affect glucose and lipid metabolism, although suppression of inflammation may partially counterbalance their skeletal effects. Disease-Modifying Antirheumatic Drugs (DMARDs), particularly biologic and targeted synthetic therapies, generally improve inflammatory control and may help preserve BMD but recent evidence suggests that bone loss can persist despite effective disease control. Metabolic syndrome is also common in RA and contributes substantially to cardiovascular risk. The relationship between RA and lipid abnormalities is complex because active inflammation may suppress circulating lipid concentrations despite increased cardiovascular risk. This narrative review summarizes current evidence regarding BMD changes, osteoporosis, glucocorticoid exposure, DMARD therapy, vitamin D status, metabolic abnormalities, sarcopenia and cardiovascular risk in patients receiving long-term treatment for RA. An integrated approach combining disease control, fracture-risk assessment, BMD monitoring, glucocorticoid minimization, metabolic screening, lifestyle modification and cardiovascular risk management is essential for comprehensive long-term care.

rheumatoid arthritisbone mineral densityosteoporosisglucocorticoid-induced osteoporosis
مقالوصول مفتوح2026

Rapid Prototyping of Compartmentalized 3D Microfluidic Devices for Organotypic Cell Culture

Micromachines · مجلد 17 (5) · 609-609

We present a modular microfluidic platform for constructing miniaturized, compartmentalized cell culture systems that support monoculture, co-culture, and organ-on-a-chip models of human tissues. The devices provide architecturally defined three-dimensional microenvironments in which heterogeneous cell populations can be cultured in close proximity while maintaining precise spatial organization and independent access to each compartment. In vivo-like perfusion into, from, and between adjacent chambers is achieved via micro-engineered porous barriers that act as perfusion microchannels, enabling controlled convective and diffusive transport and recapitulating paracrine signaling between tissue units. As a proof of concept, we implement an adipose-immune co-culture model that reproduces key features of inflamed, insulin-resistant adipose tissue, including altered cytokine secretion and glucose uptake. Together, these features establish a versatile platform for the biofabrication of customizable single-organ and multi-organ in vitro models that more faithfully recapitulate human tissue structure and function for applications in disease modeling, immunometabolic studies, and preclinical drug testing.

organ-on-a-chipco-cultureporous barriersparacrine signaling
مقالمفتوح (مستودع)2026

Nrf-2/HO-1 modulatory effects on Ocimum gratissimum flavonoid-rich leaf extract in the livers of streptozotocin-induced diabetic rats

Nutrire · مجلد 51 (1)

Abstract The present study examined the modulatory effects of Ocimum gratissimum leaf flavonoid-rich extracts on the Nrf-2 and HO-1 pathways in the livers of streptozotocin-induced diabetic rats. The animals were divided into five groups ( n = 8). These included a normal control, a diabetic control, diabetic rats administered low (LDOGFL) or high (HDOGFL) doses of Ocimum gratissimum leaf flavonoid-rich extracts at 150 and 300 mg/kg, respectively, and diabetic rats administered 200 mg/kg metformin. The animals were sacrificed on the 22nd day of the study, the liver was excised, and different biochemical parameters were evaluated. At the end of this study, diabetic rats administered LDOGFL and HDOGFL presented significant ( p < 0.05) decreases in fragmented DNA, protein carbonyl and lipid peroxidation levels, as well as glucose-6-phosphatase, and fructose 1,6 bisphosphatase activities. However, there was a significant ( p < 0.05) increase in the levels of antioxidant biomarkers; phosphatase and transaminase activities; GLUT 2 and glycogen levels; glycogen synthase and phosphorylase; hexokinase, pyruvate kinase and glucose-6-phosphate dehydrogenase activities; and serum albumin and insulin in diabetic rats treated with extracts. Furthermore, there was a substantial increase in the relative gene expression of Nrf2 and HO-1, especially in diabetic rats administered LDOGFL. Hence, these findings suggest that these extracts might be helpful in managing hepatopathy in patients with diabetes mellitus.

Ocimum gratissimumNrf2heme oxygenase-1streptozotocin-induced diabetes
مراجعةمفتوح (مستودع)202542استشهاد· Semantic Scholar

Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies

Food Science & Nutrition · مجلد 13 (1) · e4682-e4682

Luteolin is widely distributed phytochemical, a flavonoid, in kingdom plantae. Luteolin with potential antioxidant activity prevent ROS-induced damages and reduce oxidative stress which is mainly responsible in pathogenesis of many diseases. Several chemo preventive activities and therapeutic benefits are associated with luteolin. Luteolin prevents cancer via modulation of numerous pathways, that is, by inactivating proteins; such as procaspase-9, CDC2 and cyclin B or upregulation of caspase-9 and caspase-3, cytochrome C, cyclin A, CDK2, and APAF-1, in turn inducing cell cycle arrest as well as apoptosis. It also enhances phosphorylation of p53 and expression level of p53-targeted downstream gene. By Increasing BAX protein expression; decreasing VEGF and Bcl-2 expression it can initiate cell cycle arrest and apoptosis. Luteolin can stimulate mitochondrial-modulated functions to cause cellular death. It can also reduce expression levels of p-Akt, p-EGFR, p-Erk1/2, and p-STAT3. Luteolin plays positive role against cardiovascular disorders by improving cardiac function, decreasing the release of inflammatory cytokines and cardiac enzymes, prevention of cardiac fibrosis and hypertrophy; enhances level of CTGF, TGFβ1, ANP, Nox2, Nox4 gene expressions. Meanwhile suppresses TGFβ1 expression and phosphorylation of JNK. Luteolin helps fight diabetes via inhibition of alpha-glucosidase and ChE activity. It can reduce activity levels of catalase, superoxide dismutase, and GS4. It can improve blood glucose, insulin, HOMA-IR, and HbA1c levels. This review is an attempt to elaborate molecular targets of luteolin and its role in modulating irregularities in cellular pathways to overcome severe outcomes during diseases including cancer, cardiovascular disorders, diabetes, obesity, inflammation, Alzheimer's disease, Parkinson's disease, hepatic disorders, renal disorders, brain injury, and asthma. As luteolin has enormous therapeutic benefits, it could be a potential candidate in future drug development strategies.

luteolinflavonoidsantioxidant activityanticancer activity
مراجعةوصول مفتوح20256استشهاد· Semantic Scholar

Efficacy of Gut Microbiome-Targeted Therapies in Modulating Systemic Inflammation and Low-Grade Chronic Inflammatory States in Adults With Metabolic Disorders: A Systematic Review

Cureus · مجلد 17 (9) · e92881-e92881

Gut microbiome-targeted therapies have shown promise in promoting the outcomes of metabolic inflammation-related disease management. This review aims to assess the effectiveness of microbiome-targeted interventions and pinpoint the most promising therapies for clinical implementation. Following the PRISMA 2020 standards, we searched four main databases: PubMed, EMBASE, Scopus, and the Cochrane Library. We integrated medical subject headings (MeSH) and free-text keywords search pertinent to gut microbiome-targeted interventions, along with related outcomes such as inflammation and insulin resistance. English studies were conducted on primary adults with a metabolic disease diagnosis or deemed a high risk, and were mandated to report at least one outcome pertinent to metabolic health or systemic inflammation. To assess the risk bias, data were extracted, and the Cochrane Risk of Bias (RoB) 2.0 tool was employed. Fifteen studies fulfilled the inclusion criteria. A narrative synthesis was conducted. We found that probiotics significantly enhanced insulin resistance (HOMA-IR), reduced circulating endotoxin levels, decreased visceral fat, BMI, and fat mass, and increased beneficial taxa with obesity-associated bacteria reduction. However, inconsistent outcomes were shown for lipid parameters. Prebiotic therapies showed significant decreases in fasting glucose in overweight people, and insulin levels and HOMA-IR in patients with metabolic syndrome, enhanced anti-inflammatory effects (31% C-reactive protein (CRP) reduction, decreased interleukin (IL)-6, tumor necrosis factor-alpha (TNF)-α, and lipopolysaccharide (LPS) levels), and promoted butyrate-producing bacteria. Synbiotic interventions showed complementary benefits for glucose metabolism and body composition. Fecal microbiota transplantation (FMT) studies indicated improved insulin sensitivity and donor microbiota engraftment in responders. Fiber-rich diet trials markedly improved HbA1c levels in diabetic and prediabetic individuals. In conclusion, prebiotics demonstrated the most consistent metabolic and anti-inflammatory benefits across multiple parameters. Probiotics showed targeted effects on insulin resistance and body composition but inconsistent lipid outcomes. FMT and synbiotics require further investigation to establish clinical efficacy. This evidence supports prebiotics as a priority intervention for metabolic disease management through microbiome modulation.

systemic inflammationlow-grade inflammationmetabolic disordersprobiotics
مقالوصول مفتوح20254استشهاد· Semantic Scholar

Telmisartan targets Nrf2-HO1 axis in MASLD modulating oxidative stress, inflammation, and mitochondrial dysfunction: mechanistic insights

Libyan Journal of Medicine · مجلد 20 (1) · 2585617-2585617

Metabolically dysfunction-associated steatotic liver disease (MASLD) has emerged as the leading chronic liver disease worldwide, driven primarily by metabolic derangement. The current investigation proposes to elucidate the hepatoprotective mechanisms of telmisartan (TEL) in MASLD. Twenty-four male Wistar rats were allocated to four groups (Control, MASLD, TEL-treated, and MASLD/TEL). Lipid profiles, glycemic markers, liver enzymes, and hepatic markers of oxidative stress (malondialdehyde (MDA), glutathione (GSH), superoxide dismutase (SOD), and catalase) were measured. MASLD-associated genes retrieved from GeneCards® were mapped to Rattus norvegicus ortholog genes using the gprofiler2 R package. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Reactome enrichment analyses were subsequently performed using the clusterProfiler R package. Hepatic inflammatory cytokines (TNF-β, IL-6, and NF-κB), mitochondrial respiratory enzymes (Complexes I–IV), and the gene expression of Nrf2, HO-1, MMP-9, and TIMP-1 were evaluated using spectrophotometric assays for mitochondrial respiratory enzymes. Histological assessment was done using Hematoxylin and Eosin (H&E) staining, Masson's trichrome, and TGF-β immunostaining. TEL ameliorates MASLD-associated disturbances in the serum ALT level and lipid profile. It significantly reduces the levels of oxidative stress markers. KEGG and Reactome enrichment highlighted pathways involved in lipid metabolism, insulin resistance, and inflammation, with the peroxisome proliferator–activated receptor (PPAR) and AMP-activated protein kinase (AMPK) signaling pathways being the most enriched. TEL treatment increased the hepatic expression of Nrf2, HO-1, and TIMP−1 while decreasing the expression of MMP-9. The levels of the proinflammatory cytokines TNF-α and IL-6 decreased. The activities of mitochondrial enzymes (citrate synthase and complex I) improved. MASLD induced marked hepatic fibrosis, which was markedly improved following TEL treatment. TEL has notable hepatoprotective properties in MASLD by enhancing metabolic parameters, decreasing oxidative stress, and moderating inflammatory reactions.

telmisartannon-alcoholic fatty liver diseaseNrf2/HO-1 pathwayoxidative stress
مراجعةوصول مفتوح20254استشهاد· Semantic Scholar

Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease: A Systematic Review of Randomized Controlled Trials

Cureus · مجلد 17 (6) · e86232-e86232

Nonalcoholic fatty liver disease (NAFLD) is a common comorbidity in individuals with type 2 diabetes mellitus (T2DM), contributing to increased liver-related complications and cardiovascular risk. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as potential treatments offering benefits for both metabolic and liver-related outcomes. This systematic review evaluated the efficacy of SGLT2 inhibitors in improving hepatic steatosis, liver enzymes, glycemic control, and liver histology in patients with T2DM and NAFLD. The review was conducted using a structured methodology, including systematic database searches and risk of bias assessments. Included randomized controlled trials (RCTs) investigated various SGLT2 inhibitors, such as dapagliflozin, empagliflozin, ertugliflozin, and ipragliflozin. Most studies showed significant reductions in liver fat content, improvements in serum liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT)), and favorable effects on blood pressure, triglycerides, and body composition. Glycemic control markers, including glycated hemoglobin (HbA1c), fasting glucose, and insulin resistance indices, also improved. One biopsy-based study demonstrated histological improvements, including reduced fibrosis and resolution of nonalcoholic steatohepatitis (NASH). No serious adverse events were reported. These findings suggest SGLT2 inhibitors may offer dual benefits for managing both diabetes and fatty liver disease. Further long-term studies focusing on liver histology as a primary endpoint are needed to confirm these effects.

SGLT2 inhibitorstype 2 diabetesnon-alcoholic fatty liver diseasedapagliflozin
مقالمفتوح (مستودع)20253استشهاد· Semantic Scholar

Biochemical and Histological Analyses of Taurine’s Therapeutic Triad: Antidiabetic, Antioxidant, and Anti-inflammatory Effects in Alloxan-induced Diabetic Rats

Journal of Anatomical Society of India · مجلد 74 (2) · 92-103

Background: Diabetes mellitus poses a significant health challenge worldwide. Oxidative stress, altered lipid profile, and inflammation are linked to diabetic complications. Objective: This work aimed to assess the effects of taurine (TAU) in alloxan (ALX)-induced diabetes in rats, evaluating its antihyperglycemic, antidyslipidemic, antioxidant, and anti-inflammatory effects. In addition, evaluating the effect of TAU on hepatic, renal, and cardiac complications. Materials and Methods: Fifty rats were divided into four groups, control, TAU, ALX, and ALX + TAU. At the end of the experiment, blood and tissue were collected and subjected to serum glucose, insulin, lipid profile, liver enzyme, creatinine, urea detection, oxidative-antioxidant parameters evaluation, inflammatory, anti-inflammatory cytokines detection, and histological evaluation. Results: Experimental results demonstrated that TAU effectively mitigated hyperglycemia, dyslipidemia, oxidative stress, and inflammatory conditions induced by ALX. TAU treatment improved serum glucose and insulin levels, restored lipid profiles, enhanced antioxidant enzyme activities, and reduced lipid peroxidation. In addition, TAU ameliorated hepatic and renal function alterations preserved histological architecture in the pancreas, liver, kidney, and heart tissues, and modulated inflammatory responses by diminishing the inflammatory mediators interleukin-6 (IL-6) and tumor necrosis factor-α while augmenting the anti-inflammatory mediator IL-10. Conclusions: TAU exerts a therapeutic effect on ALX-induced hepatic, renal, and cardiac diabetic complications by lowering blood glucose levels, augmenting insulin secretion, ameliorating dyslipidemia, preserving the oxidative-redox balance, and boosting antioxidant activity. TAU has also an anti-inflammatory impact.

taurinealloxan-induced diabetesdiabetes mellitusantidiabetic effect